On 5 July, at the Royal Palace in Fez, the King of Morocco chaired a ceremony to launch and sign agreements relating to the project for the manufacture and fill-finish in Morocco of the anti-Covid-19 vaccine and other vaccines. This ambitious structuring project is part of the Royal will to equip the country with complete and integrated industrial and biotechnological capabilities dedicated to the manufacture of vaccines in Morocco. After a first stage that focused on the production of 5 million doses of the Sinopharm vaccine, the second phase has been launched with the establishment of governance and project management. Thus, the company Morocco Sino Pharma, created in March 2021, changed its corporate purpose and its name on 1st September. It is now called BAB consortium SA and its corporate purpose now allows it to carry out all industrial projects, to trade in all goods and to acquire stakes in any existing companies or companies being formed.
